Oncolytics Biotech Management
Management criteria checks 2/4
Oncolytics Biotech's CEO is Jared Kelly, appointed in Jun 2025, has a tenure of less than a year. directly owns 0.052% of the company’s shares, worth CA$66.52K. The average tenure of the management team and the board of directors is 3.7 years and 4.8 years respectively.
Key information
Jared Kelly
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.05% |
| Management average tenure | 3.7yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?
Jan 28
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31CEO
Jared Kelly
Mr. Jared Kelly, J.D., L.L.M, was Senior VP, General Counsel & Corporate Secretary of Ambrx Biopharma Inc. from June 2023 until 2024. Mr. Kelly has extensive experience of advising public companies on corp...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 12.8yrs | CA$1.01m | 0.16% CA$ 198.1k | |
| Chief Medical Officer | 3.7yrs | CA$1.17m | 0.15% CA$ 195.5k | |
| Vice President of Product Development | 6.8yrs | CA$635.84k | 0.070% CA$ 89.6k | |
| Vice President of Clinical Operations | 2.6yrs | CA$654.71k | no data | |
| CEO & Director | less than a year | no data | 0.052% CA$ 66.5k | |
| Director of Investor Relations & Communication | no data | no data | no data | |
| Chief Business Officer | less than a year | no data | 0.026% CA$ 33.7k | |
| Consultant | 6.3yrs | CA$25.98k | no data |
Experienced Management: ONC's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.052% CA$ 66.5k | |
| Independent Director | 10.2yrs | CA$103.35k | 0.38% CA$ 484.4k | |
| Independent Director | 3.2yrs | CA$94.72k | 0.033% CA$ 42.0k | |
| Independent Director | 3yrs | CA$87.52k | 0.044% CA$ 56.4k | |
| Chairman of the Board | 12.3yrs | CA$424.23k | 0.27% CA$ 341.0k | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Independent Director | 1.6yrs | CA$108.36k | 0.044% CA$ 56.4k | |
| Independent Director | 11.2yrs | CA$110.55k | 0.19% CA$ 242.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Independent Director | 7.8yrs | CA$104.79k | 0.088% CA$ 112.0k | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data |
Experienced Board: ONC's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/06 10:53 |
| End of Day Share Price | 2025/08/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncolytics Biotech Inc. is covered by 22 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Douglas Loe | Echelon Wealth Partners Inc. |